

Luminous Mind, Inc. Welcomes Prof. Mariko Gakiya to its Management Team

Boston, MA – July 15, 2025 - Luminous Mind, Inc. (LMI), a pioneering biopharmaceutical company dedicated to revolutionizing the treatment landscape for neuropsychiatric disorders, proudly announces the addition of Prof. Mariko Gakiya to its management team.

Prof. Mariko Gakiya is a global expert in leadership innovation, organizational change, and strategic partnerships, grounded in a deep understanding of human development and social policy. She is helping LMI to build strategic partnerships with Japanese pharmaceutical companies and leading academic institutions worldwide. Her work is focused on advancing women's health, particularly in the areas of preventive care and holistic wellness. She addresses critical issues such as depression and vasomotor symptoms (VMS)—commonly known as "hot flashes." LMI's lead therapeutic candidate is specifically designed to target these unmet needs, especially in cancer therapy, where no FDA-approved treatments for emergent VMS currently exist.

Louis Herlands, Ph.D., Chairman and CEO of Luminous Mind, expressed his excitement about Prof. Gakiya, stating, "With decades of experience advising institutions across academia, industry, and government, she specializes in forging transformational alliances in cross-cultural contexts." Herlands continued, "We are excited about her joining our team."



Previously, she served as Vice President of Organizational Development at Morgan Stanley and as Executive Director of the Inamori Foundation's Institute for Environment, Civilization, and Ethics. Prof. Gakiya actively engages with executive boards of public-private partnerships, providing strategic counsel to leaders within international development agencies, philanthropic foundations, corporate entities, and institutions of higher learning. Additionally, she served as the Founding Faculty Director of the Global Leadership Program at the Graduate School of Medicine at the University of Tokyo and has held faculty and advisory committee positions at Harvard University and other esteemed institutions.

Commenting on her new role, Prof. Gakiya stated, "I am honored to join Luminous Mind's management team and look forward to contributing to the company's groundbreaking work in CNS therapeutics, especially women's health issues. Together with Louis and the rest of the Luminous Mind team, I look forward to driving innovation and making a meaningful impact on the lives of patients worldwide."

About Luminous Mind, Inc.:

Luminous Mind Inc., with its focus on Central Nervous System (CNS) disorders, applies a rigorous therapeutic discovery and development process that includes the repurposing of existing, abandoned, and developmental compounds for new indications. Groundbreaking scientific insights in neuroscience, genetics, systems biology, and brain circuitry, together with powerful new tools, drive its discovery efforts. For additional information, please visit www.LuminousMindlnc.com.

Contact:

Louis Herlands, Ph.D. Chairman and CEO

Email: LHerlands@LuminousMindInc.com

Phone: 800-816-9630 ext. 702 Location: Cambridge, MA